Pentadeca Arginate

Pentadeca arginate is a very new, experimental peptide marketed within the largely unregulated research-peptide space, and no peer-reviewed clinical or preclinical study dedicated to this specific compound was retrieved for this entry, so its evidence base should be regarded as essentially absent. ^[1] The most closely studied pentadecapeptide, the body protection compound BPC-157 isolated from gastric juice, has itself demonstrated regenerative properties largely in animal models but has not been approved by the FDA, with human data limited to only a few small pilot studies. ^{[1] [2]}

For the closest studied pentadecapeptide, inconsistent preparation standards, limited clinical validation, and regulatory restrictions underscore the need for rigorous controlled trials before any clinical use can be recommended. ^[2] Until well-designed human trials are conducted, such peptides should be considered investigational and their use approached with caution. ^[1]